Information Provided By: 
Fly News Breaks for December 13, 2016
LIFE
Dec 13, 2016 | 12:28 EDT
JPMorgan analyst Cory Kasimov downgraded aTyr Pharma to Neutral from Overweight saying the company's Phase 1/2 data for Resolaris from three different studies is a "mixed bag." The data announced today still don't fully define proof-of concept, Kasimov tells investors in a research note. He thinks the company will need time to establish a clear path forward. Kasimov has no target for the shares. aTyr shares are down 80c to $2.85 in afternoon trading.
News For LIFE From the Last 2 Days
There are no results for your query LIFE
